Saline Versus Lactated Ringer's Solution: The SOLAR Fluid Trial
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT02565420|
Recruitment Status : Completed
First Posted : October 1, 2015
Last Update Posted : January 10, 2019
Perioperative volumes of saline cause a mild acidosis compared with buffered fluids. On the other hand, saline administration maintains plasma osmolality and better repletes vascular volume which is an important goal of perioperative fluid administration. Currently, there is no convincing evidence that either saline or buffered solutions are preferable. Consequently, both types of fluid remain in common use at the Clinic and worldwide.
There has never been a large trial of perioperative saline and balanced salt solutions comparing the incidence of major complications including acute kidney injury. The investigators primary objective is thus to determine the relative safety of perioperative saline and lactated Ringer's solution. Specifically, the investigators propose to test the:
- Primary hypothesis that a composite of major in-hospital postoperative complications is lower in patients given lactated Ringer's solution compared to normal saline.
- Secondary hypothesis that acute kidney injury, measured by AKIN criteria, is lower in patients given lactated Ringer's solution compared to normal saline.
The acquisition cost of saline and lactated Ringer's solutions is similar in the United States. (Curiously, buffered solutions are far more expensive than saline in Great Britain.) But to the extent that one fluid or the other provokes more complications, cost of care may be increased with that fluid selection. Cost may also be increased by the need for additional electrolyte monitoring and electrolyte replacement.
The investigators will therefore secondarily conduct an economic evaluation to determine the relative incremental hospital cost of each fluid. To the extent that one fluid or the other reduces cost (assuming similar complication rates), the Clinic will be able to reduce cost by specifying the appropriate fluid without impairing quality.
Evidence that one fluid or the other causes few complications would be a strong quality indicator that the Clinic should standardize perioperative fluid selection.
|Condition or disease||Intervention/treatment||Phase|
|Postoperative Complications||Other: Normal saline Other: Lactated Ringer's solution||Not Applicable|
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||8616 participants|
|Intervention Model:||Sequential Assignment|
|Intervention Model Description:||Alternating intervention|
|Masking:||None (Open Label)|
|Official Title:||Saline Versus Lactated Ringer's Solution: The SOLAR Fluid Trial|
|Study Start Date :||September 2015|
|Actual Primary Completion Date :||October 2018|
|Actual Study Completion Date :||January 2019|
Active Comparator: Lactated Ringer's solution
During the perioperative period of the colorectal, orthopedic or similar surgery the patient will receive an intervention of Lactated Ringer's solution fluids.
Other: Lactated Ringer's solution
Patients will be administered Lactated Ringer's solution for intraoperative fluid management.
Placebo Comparator: normal saline
During the perioperative period of the colorectal, orthopedic or similar surgery the patient will receive an intervention of normal saline solution.
Other: Normal saline
Patients will be administered normal saline for intraoperative fluid management.
- Major Post Operative Complications [ Time Frame: After surgery through hospital discharge ]Major complications include in-hospital mortality, renal (AKIN criteria 2+), respiratory, infectious, and hematological complications.
- Economic evaluation [ Time Frame: After surgery through hospital discharge ]The evaluation will determine the incremental costs between the two interventions; uncomplicated care and care of complications, as well as a combined incremental cost.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02565420
|United States, Ohio|
|General Anesthesia, Anesthesia Institute|
|Cleveland, Ohio, United States, 44195|
|Study Chair:||Daniel Sessler, M.D.||Chair, Outcomes Research|